These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9240185)

  • 21. Clinical characteristics of alpha-blocker responders in men with benign prostatic hyperplasia.
    Mimata H; Satoh F; Ohno H; Miyoshi M; Nomura Y
    Urol Int; 2002; 68(4):237-42. PubMed ID: 12053024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
    Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
    Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia.
    Tsukamoto T; Endo Y; Narita M
    Int J Urol; 2009 Sep; 16(9):745-50. PubMed ID: 19674165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
    El-Tatawy H; Gameel T; El-enen MA; Hagras A; Mousa A; El-Bahnasy AH; Raheem AA; Abu-dewan K
    Arch Ital Urol Androl; 2015 Sep; 87(3):238-42. PubMed ID: 26428648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical efficacy and reduction effect on prostatic volume of chlormadinone acetate combined with tamsulosin hydrochloride in benign prostatic hyperplasia patients insufficiently treated with tamsulosin hydrochloride only].
    Ueki O; Kawaguchi K; Katsumi T; Murayama K; Kameda K; Nishino A; Sakai A; Haginaka T; Miyazaki K; Asari T; Egawa M
    Hinyokika Kiyo; 1998 Aug; 44(8):565-73. PubMed ID: 9783192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity?
    Bozlu M; Ulusoy E; Doruk E; Cayan S; Canpolat B; Schellhammer PF; Akbay E
    Urology; 2003 Dec; 62(6):1050-3. PubMed ID: 14665353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Can PSA density predict the response to alpha-blockers in benign prostatic hyperplasia?].
    Server Pastor G; Nicolás Torralba JA; Bañón Pérez V; Valdelvira Nadal P; Rigabert Montiel M; López Cubillana P; Prieto González A; García Hernández JA; Pérez Albacete M
    Actas Urol Esp; 2001 Feb; 25(2):115-8. PubMed ID: 11345794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Urodynamic evaluation of alpha-1 blocker tamsulosin on benign prostatic hyperplasia using pressure-flow study].
    Miyatake R; Park YC; Koike H; Ohnishi N; Sugiyama T; Kurita T; Esa A; Kiwamoto H
    Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1048-55. PubMed ID: 8831212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia.
    Noguchi K; Suzuki K; Teranishi J; Kondo K; Kishida T; Saito K; Uemura H; Kubota Y
    Hinyokika Kiyo; 2006 Jul; 52(7):527-30. PubMed ID: 16910584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
    Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
    Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
    J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
    Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
    Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms.
    Witjes WP; Aarnink RG; Ezz-el-Din K; Wijkstra H; Debruyne EM; de la Rosette JJ
    Br J Urol; 1997 Jul; 80(1):84-90. PubMed ID: 9240186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].
    Debruyne F; Boyle P; Calais da Silva F; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP; Schulman C
    Prog Urol; 2004 Jun; 14(3):326-31. PubMed ID: 15373174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.